We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
David Thompson has left Azure Biotech, the company he helped launch, to join Inozyme Pharma in a newly created position as senior vice president and chief scientific officer.
The mission is to help babies with very rare disorders caused by mineral imbalances that can lead to overcalcification of soft tissues and undermineralization of bone, and can all too often cause death.